Apoptosis for prediction of radiotherapy late toxicity: lymphocyte subset sensitivity and potential effect of TP53 Arg72Pro polymorphism.
We tested apoptosis levels in in vitro irradiated T-lymphocytes from breast cancer (BC) patients with radiotherapy-induced late effects. Previous results reported in the literature were revised. We also examined the effect of TP53 Arg72Pro polymorphism on irradiation-induced apoptosis (IA). Twenty BC patients, ten with fibrosis and/or telangiectasias and ten matched controls with no late reactions, were selected from those receiving radiotherapy between 1993 and 2007. All patients were followed-up at least 6 years after radiotherapy. Using the combination of both CD3 and CD8 antibodies the in vitro IA was measured in CD3, CD8 and CD4 T-lymphocytes, and CD8 natural killer lymphocytes (CD8 NK) by flow cytometry. The TP53 Arg72Pro genotype was determined by sequencing. Patients with late radiotherapy toxicity showed less IA for all T-lymphocytes except for the CD8 NK. CD8 NK showed the highest spontaneous apoptosis and the lowest IA. IA in patients with toxicity appears to be lower than the control patients only in TP53 Arg/Arg patients (P = 0.077). This difference was not present in patients carrying at least one Pro allele (P = 0.8266). Our data indicate that late side effects induced by radiotherapy of BC are associated to low levels of IA. CD8 NK cells have a different response to in vitro irradiation compared to CD8 T-lymphocytes. It would be advisable to distinguish the CD8 NK lymphocytes from the pool of CD8+ lymphocytes in IA assays using CD8+ cells. Our data suggest that the 72Pro TP53 allele may influence the IA of patients with radiotherapy toxicity.
Radiation Oncology Department, Santa Creu i Sant Pau Hospital, Barcelona, Spain.
María J
MJ
Fuentes-Raspall
Isabel
I
Caragol
Carmen
C
Alonso
Teresa
T
Ramón y Cajal
David
D
Fisas
Alejandro
A
Seoane
Nerea
N
Carvajal
Sandra
S
Bonache
Orland
O
Díez
Sara
S
Gutiérrez-Enríquez
D000328:Adult; D017209:Apoptosis / Q000528:radiation effects; D001943:Breast Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology / Q000528:radiation effects*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000473:pathology / Q000528:radiation effects*; D016022:Case-Control Studies; D002478:Cells, Cultured; D005260:Female; D005355:Fibrosis; D005720:Gamma Rays / Q000009:adverse effects*; D015870:Gene Expression; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology / Q000473:pathology / Q000528:radiation effects*; D016131:Lymphocyte Subsets / Q000276:immunology / Q000473:pathology / Q000528:radiation effects*; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011379:Prognosis; D011446:Prospective Studies; D011836:Radiation Tolerance; D013684:Telangiectasis / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000235:genetics* / Q000378:metabolism
C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53